Artificial intelligence-based prediction of diabetic retinopathy evolution (EviRed): protocol for a prospective cohort

Author:

Tadayoni Ramin,Massin Pascale,Bonnin SophieORCID,Magazzeni Stéphanie,Lay Bruno,Le Guilcher Alexandre,Vicaut Eric,Couturier Aude,Quellec Gwenolé,Investigators EviRed

Abstract

IntroductionAn important obstacle in the fight against diabetic retinopathy (DR) is the use of a classification system based on old imaging techniques and insufficient data to accurately predict its evolution. New imaging techniques generate new valuable data, but we lack an adapted classification based on these data. The main objective of the Evaluation Intelligente de la Rétinopathie Diabétique, Intelligent evaluation of DR (EviRed) project is to develop and validate a system assisting the ophthalmologist in decision-making during DR follow-up by improving the prediction of its evolution.Methods and analysisA cohort of up to 5000 patients with diabetes will be recruited from 18 diabetology departments and 14 ophthalmology departments, in public or private hospitals in France and followed for an average of 2 years. Each year, systemic health data as well as ophthalmological data will be collected. Both eyes will be imaged by using different imaging modalities including widefield photography, optical coherence tomography (OCT) and OCT-angiography. The EviRed cohort will be divided into two groups: one group will be randomly selected in each stratum during the inclusion period to be representative of the general diabetic population. Their data will be used for validating the algorithms (validation cohort). The data for the remaining patients (training cohort) will be used to train the algorithms.Ethics and disseminationThe study protocol was approved by the French South-West and Overseas Ethics Committee 4 on 28 August 2020 (CPP2020-07-060b/2020-A01725-34/20.06.16.41433). Prior to the start of the study, each patient will provide a written informed consent documenting his or her agreement to participate in the clinical trial. Results of this research will be disseminated in peer-reviewed publications and conference presentations. The database will also be available for further study or development that could benefit patients.Trial registration numberNCT04624737

Funder

Agence Nationale de la Recherche

Publisher

BMJ

Reference33 articles.

1. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045

2. Prevalence of diabetic retinopathy in the US in 2021;Lundeen;JAMA Ophthalmol,2023

3. Epidemiology of diabetic retinopathy: Expected vs reported prevalence of cases in the French population

4. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications—risks and mitigation

5. Davis MD . The Airlie classification of diabetic retinopathy. In: Goldberg MF , Fine S , eds. Symposium on the Treatment of Diabetic Retinopathy: Public Health Service Publication no.1890. Washington, DC: US Government Printing Offic,

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3